A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE3

Conditions

Esophageal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen University Cancer Center, Guangzhou, China
Contact: Study coordinator (Ruihua Xu) · rhuaxu@163.com · 020-87343795

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2, PHASE3

Beijing, China

Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE3

Montreal, Canada · Dublin, Ireland

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Xi'an, China

Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Xi'an, China